Trials / Completed
CompletedNCT01516567
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab | 6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2017-04-01
- Completion
- 2022-11-16
- First posted
- 2012-01-25
- Last updated
- 2026-02-09
Locations
9 sites across 9 countries: Belgium, Canada, France, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01516567. Inclusion in this directory is not an endorsement.